Holen Sie sich die Stockscreener-App
49.38
1.42%
-0.71
Handel nachbörslich:
49.38
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Lifesci Capital Analysts Raise Earnings Estimates for AKRO - MarketBeat
Published on: 2025-08-15 12:12:33 - metal.it
EFX's 96-Week HARMONY Trial: A Paradigm Shift in MASH Treatment and a High-Conviction Buy Case for AKRO - AInvest
Akero Therapeutics Announces Lancet Publication of the - GlobeNewswire
Nearly Half of Patients See Liver Fibrosis Improvement: Akero's EFX Drug Shows Promise in 96-Week MASH Study - Stock Titan
Akero Therapeutics: Contrarian Opportunity Amid FDA Approval and Insider Selling - AInvest
Reversing Akero Therapeutics Contrarian Buy Rating to Contrarian Sell Rating - AInvest
Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating - Seeking Alpha
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - Zacks Investment Research
66,422 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Informed Momentum Co LLC - MarketBeat
Insider Selling and Market Confidence at Akero Therapeutics: A Balancing Act of Strategy and Optimism - AInvest
Akero Therapeutics Insider Sold Shares Worth $1,457,596, According to a Recent SEC Filing - MarketScreener
Akero Therapeutics Insider Sold Shares Worth $597,326, According to a Recent SEC Filing - MarketScreener
Akero Therapeutics COO Young sells $597k in shares - Investing.com
Akero Therapeutics CEO Cheng sells $1.46 million in stock - Investing.com
Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
20,253 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Aigen Investment Management LP - MarketBeat
Sentiment Turns Positive on Akero Therapeutics Inc. — Reversal AheadTrade Performance Summary & Weekly Momentum Picks - metal.it
Vivo Capital LLC Invests $8.14 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics director Henderson sells $142k in shares By Investing.com - Investing.com South Africa
Akero therapeutics director Henderson sells $142k in shares - Investing.com
Jefferies Financial Group Inc. Makes New $324,000 Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.8%Here's Why - MarketBeat
Akero Therapeutics Maintains Buy Rating Amid Strong Financial Position and Promising Clinical Developments - AInvest
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year? - Yahoo Finance
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Buy" by Analysts - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 12,500 Shares of Stock - MarketBeat
Akero Therapeutics Inc. Hits Price Floor — Bounce IncomingAccurate Technical Trend Reversal Picks Detected - metal.it
Using Python tools to backtest Akero Therapeutics Inc. strategiesValue Investing Checklist with Entry Signals - Newser
Ranking Akero Therapeutics Inc. among high performing stocks via toolsFree AI Screening for Swing Trade Picks - Newser
Akari Therapeutics Reports Q2 EPS $(0.86) vs. $(0.81) Last Year - AInvest
Why Akero Therapeutics Inc. is moving todaySwing Reversal Forecast Based on Patterns - Newser
Can you recover from losses in Akero Therapeutics Inc.High Probability Trade Plan with Indicators - Newser
Is Akero Therapeutics Inc. building a consolidation baseHigh Reward Investment Strategy for Beginners - Newser
Published on: 2025-08-09 06:15:43 - beatles.ru
Akero Therapeutics Q2 Loss Narrows by 6%, EFX Clinical Trials Progress - AInvest
When is the best time to exit Akero Therapeutics Inc.Free AI-Powered Trade Planning with Indicators - Newser
Akero Therapeutics Advances in MASH Treatment Development - TipRanks
What MACD and RSI say about Akero Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Akero Therapeutics AKRO Q2 2025 Earnings Preview Upside Potential on Efruxifermin Advancements in MASH Treatment - AInvest
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Ritu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position - TipRanks
Akero Therapeutics (NASDAQ:AKRO) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Akero Therapeutics Keeps Analysts Optimistic Despite Larger Losses - Finimize
Akero Therapeutics shares fall 1.31% intraday after Q2 net loss widens. - AInvest
Akero Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akero (AKRO) Q2 Loss Narrows 6% - AOL.com
Akero Therapeutics' Q2 2025 Financial Results and Business Update: A Deep Dive into Metabolic Disease Innovation and Shareholder Value - AInvest
Akero Therapeutics Q2 Net Loss Widens - MarketScreener
Akero Therapeutics, Inc. SEC 10-Q Report - TradingView
Akero Therapeutics Q2 net income just shy of estimates, cash position strong - MarketScreener
Earnings Flash (AKRO) Akero Therapeutics Posts Q2 Net Loss $0.86 a Share, vs. FactSet Est of $0.96 Loss - MarketScreener
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):